BR112013009255A2 - forma de dosagem oral de dissolução rápida de vacina que usa amido - Google Patents
forma de dosagem oral de dissolução rápida de vacina que usa amidoInfo
- Publication number
- BR112013009255A2 BR112013009255A2 BR112013009255A BR112013009255A BR112013009255A2 BR 112013009255 A2 BR112013009255 A2 BR 112013009255A2 BR 112013009255 A BR112013009255 A BR 112013009255A BR 112013009255 A BR112013009255 A BR 112013009255A BR 112013009255 A2 BR112013009255 A2 BR 112013009255A2
- Authority
- BR
- Brazil
- Prior art keywords
- starch
- vaccine
- dosage form
- oral dosage
- fast dissolving
- Prior art date
Links
- 229920002472 Starch Polymers 0.000 title abstract 3
- 239000008107 starch Substances 0.000 title abstract 3
- 235000019698 starch Nutrition 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 239000006186 oral dosage form Substances 0.000 title abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
forma de dosagem oral de dissolução rápida de vacina que usa amido. é preparada uma forma de dosagem de dissolução rápida (fddf) para a liberação de uma vacina, usando uma formulação que contenha um amido, opcionalmente, junto com pelo menos um agente formador de matriz adicional, preferivelmente uma combinação de gelatina e manitol, em que uma resposta imune seja induzida em um paciente necessitado.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39123810P | 2010-10-08 | 2010-10-08 | |
US61/391,238 | 2010-10-08 | ||
PCT/US2011/055689 WO2012048333A1 (en) | 2010-10-08 | 2011-10-11 | Oral vaccine fast-dissolving dosage form using starch |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013009255A2 true BR112013009255A2 (pt) | 2016-07-26 |
BR112013009255B1 BR112013009255B1 (pt) | 2021-02-23 |
Family
ID=44908091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013009255-6A BR112013009255B1 (pt) | 2010-10-08 | 2011-10-11 | composição sólida de vacina oral de dissolução rápida |
Country Status (18)
Country | Link |
---|---|
US (1) | US9956169B2 (pt) |
EP (2) | EP3095441B1 (pt) |
JP (2) | JP6061859B2 (pt) |
KR (1) | KR101751964B1 (pt) |
CN (2) | CN103347494A (pt) |
AR (1) | AR083361A1 (pt) |
AU (1) | AU2011312107B2 (pt) |
BR (1) | BR112013009255B1 (pt) |
CA (1) | CA2813146C (pt) |
DK (2) | DK2624815T3 (pt) |
ES (2) | ES2842290T3 (pt) |
HK (1) | HK1253541A1 (pt) |
HU (1) | HUE052853T2 (pt) |
MX (1) | MX347101B (pt) |
PL (1) | PL3095441T3 (pt) |
PT (1) | PT3095441T (pt) |
RU (2) | RU2639447C2 (pt) |
WO (1) | WO2012048333A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103347494A (zh) * | 2010-10-08 | 2013-10-09 | R·P·舍勒科技有限责任公司 | 使用淀粉的口服疫苗快速溶解剂型 |
US10272038B2 (en) | 2013-12-02 | 2019-04-30 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
US11033493B2 (en) | 2013-12-02 | 2021-06-15 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
US9668970B2 (en) * | 2013-12-02 | 2017-06-06 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
TWI745278B (zh) | 2014-10-10 | 2021-11-11 | 以色列商艾畢克生物實驗有限公司 | 發泡性降低之疫苗組合物 |
CN104530489B (zh) * | 2015-02-05 | 2017-07-07 | 湖南尔康制药股份有限公司 | 一种速溶于水的淀粉成膜组合物 |
CN109224191A (zh) * | 2018-07-23 | 2019-01-18 | 西安交通大学医学院第附属医院 | 一种用于静脉输液用的无菌输液港辅助植入装置 |
US11523988B2 (en) | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
JP7219853B2 (ja) | 2019-07-31 | 2023-02-08 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | 医薬製剤投薬のための密度流量計 |
AU2021343287A1 (en) | 2020-09-17 | 2023-06-01 | Catalent U.K. Swindon Zydis Limited | Use of surfactant with high molecular weight fish gelatin based dosage formulations to improve flow characteristics |
US20230364013A1 (en) | 2020-10-08 | 2023-11-16 | Catalent U.K. Swindon Zydis Limited | Stable oral dispersible formulation for epinephrine |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
CN1120310A (zh) | 1993-03-11 | 1996-04-10 | 塞科雷泰克公司 | 在粘膜表面转运免疫原的聚合粘膜粘合剂 |
GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
AU7682896A (en) * | 1995-10-13 | 1997-04-30 | Zynaxis, Inc. | Solid, orally administrable viral vaccines and methods of preparation |
GB9700878D0 (en) * | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
US5976577A (en) * | 1997-07-11 | 1999-11-02 | Rp Scherer Corporation | Process for preparing fast dispersing solid oral dosage form |
EP1579851A3 (en) * | 1997-08-29 | 2009-09-02 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of use thereof |
GB9722682D0 (en) * | 1997-10-27 | 1997-12-24 | Scherer Ltd R P | Pharmaceutical products |
US20040265377A1 (en) * | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
GB9901819D0 (en) * | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
EP2011874A1 (en) | 1999-11-12 | 2009-01-07 | Fibrogen, Inc. | Recombinant gelatin in vaccines |
EP1120109A3 (en) * | 2000-01-24 | 2002-07-10 | Pfizer Products Inc. | Rapidly disintegrating and fast dissolving solid dosage form |
GB0020089D0 (en) * | 2000-08-15 | 2000-10-04 | Smithkline Beecham Biolog | Vaccine Composition |
US6509040B1 (en) * | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
DE60307082T4 (de) * | 2002-05-07 | 2015-04-30 | Ferring B.V. | In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin |
NZ538628A (en) * | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
WO2004047793A1 (en) | 2002-11-26 | 2004-06-10 | Alk-Abelló A/S | Pharmaceutical allergen product |
US8012505B2 (en) * | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
AU2004233744A1 (en) * | 2003-05-02 | 2004-11-11 | Warner-Lambert Company Llc | Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance |
US20070014807A1 (en) | 2003-09-03 | 2007-01-18 | Maida Anthony E Iii | Multiplex vaccine |
US7972621B2 (en) * | 2004-06-03 | 2011-07-05 | R.P. Scherer Technologies, Llc | Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight |
AU2006299310A1 (en) | 2005-10-04 | 2007-04-12 | Alk-Abello A/S | Solid vaccine formulation |
US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
US20110129438A1 (en) | 2006-06-28 | 2011-06-02 | James Robert Swartz | Immunogenic protein constructs |
EP2190472A2 (en) * | 2007-08-20 | 2010-06-02 | Fraunhofer USA, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
US20090226522A1 (en) * | 2008-02-28 | 2009-09-10 | Howes Simon A M | Process to minimize polymorphism |
WO2010002418A2 (en) * | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
US20120034253A1 (en) * | 2008-09-25 | 2012-02-09 | Fraunhofer Usa, Inc. | Influenza Vaccines, Antigens, Compositions, and Methods |
KR101074271B1 (ko) * | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
WO2011026080A1 (en) * | 2009-08-31 | 2011-03-03 | Wilmington Pharmaceuticals, Llc | Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain |
DK3254676T3 (en) * | 2009-10-30 | 2019-03-11 | Ix Biopharma Ltd | QUICK-SOLVING SOLID DOSAGE FORM |
GB201009273D0 (en) | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
MX347022B (es) * | 2010-07-08 | 2017-04-07 | Wrigley W M Jun Co | Confitura con complejo de gelatina. |
CN103347494A (zh) * | 2010-10-08 | 2013-10-09 | R·P·舍勒科技有限责任公司 | 使用淀粉的口服疫苗快速溶解剂型 |
-
2011
- 2011-10-11 CN CN2011800590592A patent/CN103347494A/zh active Pending
- 2011-10-11 PL PL16178493T patent/PL3095441T3/pl unknown
- 2011-10-11 JP JP2013533011A patent/JP6061859B2/ja active Active
- 2011-10-11 EP EP16178493.9A patent/EP3095441B1/en active Active
- 2011-10-11 MX MX2013003875A patent/MX347101B/es active IP Right Grant
- 2011-10-11 ES ES16178493T patent/ES2842290T3/es active Active
- 2011-10-11 RU RU2013119946A patent/RU2639447C2/ru not_active Application Discontinuation
- 2011-10-11 CN CN201810325584.8A patent/CN108434089B/zh active Active
- 2011-10-11 EP EP11779263.0A patent/EP2624815B8/en active Active
- 2011-10-11 US US13/270,411 patent/US9956169B2/en active Active
- 2011-10-11 KR KR1020137011905A patent/KR101751964B1/ko active IP Right Grant
- 2011-10-11 HU HUE16178493A patent/HUE052853T2/hu unknown
- 2011-10-11 DK DK11779263.0T patent/DK2624815T3/en active
- 2011-10-11 AU AU2011312107A patent/AU2011312107B2/en active Active
- 2011-10-11 PT PT161784939T patent/PT3095441T/pt unknown
- 2011-10-11 WO PCT/US2011/055689 patent/WO2012048333A1/en active Application Filing
- 2011-10-11 AR ARP110103727A patent/AR083361A1/es not_active Application Discontinuation
- 2011-10-11 ES ES11779263.0T patent/ES2602506T3/es active Active
- 2011-10-11 DK DK16178493.9T patent/DK3095441T3/da active
- 2011-10-11 CA CA2813146A patent/CA2813146C/en active Active
- 2011-10-11 BR BR112013009255-6A patent/BR112013009255B1/pt active IP Right Grant
-
2016
- 2016-09-09 JP JP2016176393A patent/JP6403738B2/ja active Active
-
2017
- 2017-10-25 RU RU2017137357A patent/RU2017137357A/ru unknown
-
2018
- 2018-10-08 HK HK18112743.5A patent/HK1253541A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013009255A2 (pt) | forma de dosagem oral de dissolução rápida de vacina que usa amido | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
BR112015017451A2 (pt) | formulações farmacêuticas resistentes à violação | |
BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
CL2014002324A1 (es) | Metodo para lentificar el avance, demorar o tratar la prediabetes en un paciente con sobrepeso u obeso que comprende la administracion de empagliflozina y uno o varios fármacos antiobesidad y composición farmacéutica que comprende a dichos farmacos. | |
CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
BR112012023324B8 (pt) | processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida | |
CL2015000345A1 (es) | Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. | |
CL2013000718A1 (es) | Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades. | |
CL2013000098A1 (es) | Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. | |
BR112016002251A2 (pt) | dispositivo para administração de fármacos | |
ES2445846R1 (es) | Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos | |
BR112015021112A2 (pt) | composições farmacêuticas que compreendem everolimo | |
BR112012028773A2 (pt) | composições farmacêuticas compreendendo hidromorfona e naloxona | |
CL2013001564A1 (es) | Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica. | |
MX2016005477A (es) | Formas de dosificacion disuasivas del abuso. | |
BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
BR112012027794A2 (pt) | tablete entérico | |
BR112015014853A2 (pt) | Formulação farmacêutica, formulação farmacêutica liofilizada, uso de uma formulação farmacêutica e artigo de manufatura | |
CY1123933T1 (el) | Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης | |
ECSP12011951A (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria | |
CO6541630A2 (es) | Combinación teobromina con un descongestivo y su uso para el tratamiento de la tos | |
BR112016014530A2 (pt) | Composição para cuidado oral e uso de um copolímero de fosfato/acrilato, um agente para controle do tártaro e um veículo oralmente aceitável | |
BR112014023092A8 (pt) | Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/10/2011, OBSERVADAS AS CONDICOES LEGAIS. |